Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

NCT05533463 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced KRAS G12D Mutant Solid Tumors

Interventions

DRUG: HRS-4642

Sponsor

Jiangsu HengRui Medicine Co., Ltd.